🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Cell Therapy

DANIsh VASculitis Database (DANIVAS) NCT05935709n/a2 sites📍 Aarhus📍 Horsens Aarhus University Hospital Prophylactic Inhaled Steroids to Reduce Radiation Pneumonitis Frequency and Severity in Lung Cancer Patients NCT03803787Phase 22 sites📍 Mexico City📍 Mexico City Instituto Nacional de Cancerologia de Mexico · Tests: Inhaled budesonide Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC) NCT07627347NA1 site📍 Guangzhou Nanfang Hospital, Southern Medical University · Tests: anlotinib+bevacizumab Intranasal Breast Milk Therapy in HIE NCT06746532EARLY Phase 11 site📍 Budapest Semmelweis University · Tests: Intranasal breast milk A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy NCT07188558Phase 336 sites📍 Gilbert📍 Scottsdale📍 Scottsdale Lyell Immunopharma, Inc. · Tests: rondecabtagene autoleucel, axicabtagene ciloleucel, lisocabtagene maraleucel RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC NCT06142058n/a1 site📍 Chongqing Xueqin Yang · Tests: RecistTM criteria Bolstering Outcomes After Induction With Osimertinib Plus Chemotherapy Through Optimized Site-Directed Primary Tumor Therapy (BOOST Trial) NCT07073365Phase 21 site📍 Busan Pusan National University Hospital · Tests: Local Therapy (Surgery or Radiotherapy) Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC NCT06929936Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: Trilaciclib combined with Docetaxel Tirelizumab in Combination With Carboplatin and Albumin-binding Paclitaxel for Neoadjuvant Therapy in HNSCC NCT05941338Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Tirelizumab ,+Carboplatin+albumin-bound paclitaxel Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) NCT06780111Phase 1, Phase 252 sites📍 Pittsburgh📍 Natal📍 Porto Alegre Merck Sharp & Dohme LLC · Tests: Pembrolizumab, I-DXd, Leucovorin, Levoleucovorin, 5-Fluorouracil (5-FU) The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease NCT06608355Phase 11 site📍 Wuhan iRegene Therapeutics Co., Ltd. · Tests: Human Dopaminergic Progenitor Cells Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma NCT02605421Phase 21 site📍 Minneapolis Masonic Cancer Center, University of Minnesota · Tests: Thiotepa, Cyclophosphamide, Melphalan, Etoposide, Carboplatin Intraoral Photobiomodulation Therapy to Prevent Oral Mucositis in Patients Undergoing Hematopoietic Cell Transplantation NCT05335434NA1 site📍 Boston Dana-Farber Cancer Institute · Tests: THOR LX2.3 with LED Lollipop A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion NCT04655404EARLY Phase 121 sites📍 Aurora📍 Washington D.C.📍 Chicago Nationwide Children's Hospital · Tests: Larotrectinib, Larotrectinib surgical A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment NCT05708352Phase 25 sites📍 Los Angeles📍 San Francisco📍 Santa Monica Cedars-Sinai Medical Center · Tests: Keto Diet, Standard Anti-Cancer Diet Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel NCT06483555Phase 1, Phase 21 site📍 Chapel Hill UNC Lineberger Comprehensive Cancer Center · Tests: Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox A Prospective, Single-arm Clinical Study on the Safety and Efficacy of Ivoximab Combined With Temozolomide in the Treatment of Relapsed/Refractory Glioma NCT07599371Phase 1, Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: Ivoximab 20 mg/kg, ivgtt, Q4W, Temozolomide (TMZ) Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR) NCT05686434Phase 21 site📍 Tianjin Tianjin Medical University Cancer Institute and Hospital · Tests: Osimertinib An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors NCT07371663Phase 1, Phase 23 sites📍 Beijing📍 Zhengzhou📍 Hangzhou Beijing Tide Pharmaceutical Co., Ltd · Tests: TCC1727 tablet 90mg, TCC1727 tablet 120mg, TCC1727 tablet 160mg, benmelstobart Injection Pathological Response After Neoadjuvant Treatment on NSCLC NCT05167487n/a17 sites📍 A Coruña📍 Alicante📍 Badalona Fundación GECP · Tests: Cisplatin, Carboplatin CD70 Targeted CAR-T Cells in CD70 Positive Relapsed/Refractory Lymphoma NCT05948033Phase 1, Phase 21 site📍 Beijing Chinese PLA General Hospital · Tests: CD70-targeting CAR-T cells Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor. NCT07754409n/a1 site📍 Gothenburg Göteborg University Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma NCT06606028n/a1 site📍 San Francisco University of California, San Francisco · Tests: Blood Specimen Collection, Tumor Tissue Collection, Medical Record Review Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma NCT07538128EARLY Phase 11 site📍 Shanghai Huashan Hospital · Tests: YSCH-01, Atezolizumab (1200 mg every three weeks) A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma NCT05645107Phase 362 sites📍 Bullhead City📍 Huntington Park📍 St. Petersburg Grifols Therapeutics LLC · Tests: Xembify, Placebo Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC NCT05738434Phase 21 site📍 Zhengzhou The First Affiliated Hospital of Zhengzhou University · Tests: Camrelizumab+Apatinib+Chemotherapy→Camrelizumab+Apatinib, Camrelizumab+Chemotherapy→Camrelizumab Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia NCT06184009Phase 29 sites📍 Seoul📍 Seoul📍 Incheon Jae Wook Lee · Tests: ALL, High risk Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma NCT06160843Phase 21 site📍 Singapore National Cancer Centre, Singapore · Tests: Pembrolizumab IV infusion Q3W, with daily oral Olaparib. Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002) NCT04807140Phase 21 site📍 Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Tests: Toripalimab, nab-paclitaxel, carboplatin, Toripalimab, Surgical resection PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas NCT06530550Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: PI3K inhibitor
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy